Taysha Gene Therapies, Inc. has commenced an underwritten public offering of $200.0 million shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering aims to raise capital for the clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. All securities will be offered by Taysha, which also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered.

The offering is subject to market conditions, and there is no assurance regarding its completion, size, or terms. A shelf registration statement was filed with the Securities and Exchange Commission (SEC) on November 4, 2025, and became automatically effective upon filing. The offering will be made only by means of a written prospectus and prospectus supplement.

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor are acting as joint book-running managers for the proposed offering. Baird is serving as the lead manager. The preliminary prospectus supplement and accompanying prospectus will be available on the SEC’s website.

Taysha’s lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies. The company leverages its manufacturing process and a clinically and commercially proven AAV9 capsid to translate treatments from bench to bedside.

BMO Capital analyst Keith Tapper has maintained an Outperform rating for Taysha Gene Therapies, citing a revised valuation. The firm increased its price target for the company to $14, up from the previous target of $10.

Rating and Price Target Details

The decision to raise the price target reflects a more optimistic outlook on the stock's potential. The Outperform rating suggests that the stock is expected to perform better than the market average.